JP2004536790A5 - - Google Patents

Download PDF

Info

Publication number
JP2004536790A5
JP2004536790A5 JP2002572997A JP2002572997A JP2004536790A5 JP 2004536790 A5 JP2004536790 A5 JP 2004536790A5 JP 2002572997 A JP2002572997 A JP 2002572997A JP 2002572997 A JP2002572997 A JP 2002572997A JP 2004536790 A5 JP2004536790 A5 JP 2004536790A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
components
administered
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002572997A
Other languages
English (en)
Other versions
JP4467885B2 (ja
JP2004536790A (ja
Filing date
Publication date
Priority claimed from US09/813,018 external-priority patent/US6441026B1/en
Application filed filed Critical
Publication of JP2004536790A publication Critical patent/JP2004536790A/ja
Publication of JP2004536790A5 publication Critical patent/JP2004536790A5/ja
Application granted granted Critical
Publication of JP4467885B2 publication Critical patent/JP4467885B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Claims (19)

  1. 式1
    Figure 2004536790
    の化合物またはその誘導体と、アルキル化剤、代謝拮抗物質、紡錘体阻害剤、エピドフィロトキシン、抗生物質、酵素、トポイソメラーゼ阻害剤、白金配位錯体、または成長因子阻害剤の少なくとも一つを含んでなる医薬組成物。
  2. 抗生物質がダウノルビシン、ドキソルビシン、ブレオマイシンおよびマイトマイシンから選択される、請求項1に記載の医薬組成物。
  3. 紡錘体阻害剤がビンカアルカロイド、それらの合成もしくは半合性類似体、エストラムスチンまたはナベルビンから選択される、請求項1に記載の医薬組成物。
  4. トポイソメラーゼ阻害剤がカンプトテシン、ならびにCPT−11、トポテカンおよびピリドベンゾインドール誘導体を包含するその誘導体から選択される、請求項1に記載の医薬組成物。
  5. 白金配位錯体がシスプラチンおよびカルボプラチンから選択される、請求項1に記載の医薬組成物。
  6. 造血系の成長因子をさらに含んでなる、請求項2〜5のいずれか一項に記載の医薬組成物。
  7. 投与が個別および同時である、請求項2〜5のいずれか一項に記載の組成物の成分の投与方法。
  8. 投与が個別および逐次である、請求項2〜5のいずれか一項に記載の組成物の成分の投与方法。
  9. 投与が個別および一定時間間隔である、請求項2〜5のいずれか一項に記載の組成物の成分の投与方法。
  10. 下式:
    Figure 2004536790
    の化合物およびドキソルビシンを含んでなり、腫瘍性疾患の治療において治療的相乗作用を有する医薬組成物。
  11. 下式:
    Figure 2004536790
    の化合物およびナベルビンを含んでなり、腫瘍性疾患の治療において治療的相乗作用を有する医薬組成物。
  12. 下式:
    Figure 2004536790
    の化合物およびシスプラチンを含んでなり、腫瘍性疾患の治療において治療的相乗作用を有する医薬組成物。
  13. 下式:
    Figure 2004536790
    の化合物およびCPT11を含んでなり、腫瘍疾患の治療において治療的相乗作用を有する医薬組成物。
  14. その組成物の成分が同時投与されるものである、請求項10〜13のいずれか一項に記載の医薬組成物。
  15. 成物の複数の成分が個別投与および同時投与されるものである、請求項10〜13のいずれか一項に記載の医薬組成物。
  16. 成物の複数の成分が個別投与および半同時投与されるものである、請求項10〜13のいずれか一項に記載の医薬組成物。
  17. 成物の複数の成分が個別投与および逐次投与されるものである、請求項10〜13のいずれか一項に記載の医薬組成物。
  18. 腫瘍性疾患が乳癌である、請求項10または11に記載の医薬組成物。
  19. 腫瘍性疾患が大腸癌である、請求項12または13に記載の医薬組成物。
JP2002572997A 2001-03-21 2002-03-21 タキサン誘導体を含有する抗腫瘍組成物 Expired - Lifetime JP4467885B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/813,018 US6441026B1 (en) 1993-11-08 2001-03-21 Antitumor compositions containing taxane derivatives
PCT/IB2002/000853 WO2002074289A2 (en) 2001-03-21 2002-03-21 Antitumor compositions containing taxane derivatives

Publications (3)

Publication Number Publication Date
JP2004536790A JP2004536790A (ja) 2004-12-09
JP2004536790A5 true JP2004536790A5 (ja) 2005-12-22
JP4467885B2 JP4467885B2 (ja) 2010-05-26

Family

ID=25211230

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002572997A Expired - Lifetime JP4467885B2 (ja) 2001-03-21 2002-03-21 タキサン誘導体を含有する抗腫瘍組成物

Country Status (19)

Country Link
US (1) US6441026B1 (ja)
EP (1) EP1478355B1 (ja)
JP (1) JP4467885B2 (ja)
CN (2) CN1536995A (ja)
AT (1) ATE355837T1 (ja)
AU (1) AU2002244877B2 (ja)
BR (1) BR0208274A (ja)
CA (1) CA2440160C (ja)
CY (1) CY1106582T1 (ja)
DE (1) DE60218751T2 (ja)
DK (1) DK1478355T3 (ja)
EA (1) EA006878B1 (ja)
ES (1) ES2282400T3 (ja)
HU (1) HUP0500478A2 (ja)
IL (1) IL157992A (ja)
MX (1) MXPA03008539A (ja)
PT (1) PT1478355E (ja)
SI (1) SI1478355T1 (ja)
WO (2) WO2002074232A2 (ja)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
FR2698871B1 (fr) 1992-12-09 1995-02-24 Rhone Poulenc Rorer Sa Nouveau taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
BRPI0207961B8 (pt) * 2001-03-14 2021-05-25 Bristol Myers Squibb Co uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
ITRM20020191A1 (it) * 2002-04-08 2003-10-08 Sigma Tau Ind Farmaceuti Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patologie tumorali associate ad una alterata att
NZ535992A (en) * 2002-05-17 2008-11-28 Aventis Pharma Sa Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer
WO2004035034A2 (en) * 2002-10-16 2004-04-29 Ilex Products, Inc. Clofarabine and taxane chemotherapy combination
ITMI20030317A1 (it) * 2003-02-21 2004-08-22 Pharmacia Italia Spa Terapia combinata comprendente un derivato dell'indolopirrolocarbazolo ed un altro agente antitumorale.
WO2004103344A1 (en) * 2003-05-20 2004-12-02 Aronex Pharmaceuticals, Inc. Combination chemotherapy comprising a liposomal platinum complex
CN100340296C (zh) * 2005-02-03 2007-10-03 山东蓝金生物工程有限公司 一种抗癌体内植入剂
DK3248600T3 (da) * 2005-02-18 2020-07-06 Abraxis Bioscience Llc Kombinationer og måder til administration af terapeutiske stoffer og kombinationsterapi
US8735394B2 (en) * 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
DK2206736T3 (da) * 2005-12-05 2012-04-23 Nitto Denko Corp Polyglutamat-aminosyre-konjugater og fremgangsmåder
EP1913958B1 (en) * 2006-08-03 2009-12-23 Sanofi-Aventis Antitumor compositions containing acetylcyclopropyl docetaxel and trastuzumab
US20080181852A1 (en) * 2007-01-29 2008-07-31 Nitto Denko Corporation Multi-functional Drug Carriers
WO2008124735A2 (en) * 2007-04-10 2008-10-16 Nitto Denko Corporation Multi-functional polyglutamate drug carriers
ES2430380T3 (es) 2007-05-09 2013-11-20 Nitto Denko Corporation Composiciones que incluyen un compuesto hidrófobo y un conjugado de poliaminoácido
DK2155254T3 (da) * 2007-05-09 2013-03-04 Nitto Denko Corp Med platinlægemidler konjugerede polymere
CN101707869A (zh) * 2007-05-09 2010-05-12 日东电工株式会社 具有多种药物的聚谷氨酸盐结合物和聚谷氨酸盐-氨基酸结合物
MX2010009670A (es) * 2008-03-06 2010-09-22 Nitto Denko Corp Conjugados de paclitaxel polimericos y metodos para tratamiento de cancer.
CN105147613A (zh) 2010-03-29 2015-12-16 阿布拉科斯生物科学有限公司 增强药物递送和治疗剂有效性的方法
SG10201906075VA (en) 2010-03-29 2019-08-27 Abraxis Bioscience Llc Methods of treating cancer
WO2011153010A1 (en) 2010-06-04 2011-12-08 Abraxis Biosciences, Llc Methods of treatment of pancreatic cancer
AU2011325982C1 (en) * 2010-11-12 2015-08-20 Endocyte, Inc. Methods of treating cancer
CN102241648B (zh) * 2011-01-31 2016-08-03 沈阳东星医药科技有限公司 抗多药耐药紫杉烷类衍生物及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601676B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Procede de preparation du taxol et du desacetyl-10 taxol
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US4876399A (en) 1987-11-02 1989-10-24 Research Corporation Technologies, Inc. Taxols, their preparation and intermediates thereof
US5136060A (en) 1989-11-14 1992-08-04 Florida State University Method for preparation of taxol using an oxazinone
US5015744A (en) 1989-11-14 1991-05-14 Florida State University Method for preparation of taxol using an oxazinone
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5645988A (en) 1991-05-08 1997-07-08 The United States Of America As Represented By The Department Of Health And Human Services Methods of identifying drugs with selective effects against cancer cells
AU2005692A (en) 1991-05-08 1992-12-21 United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Method for designing cancer treatment regimens and methods and pharmaceutical compositions for the treatment of cancer
US5229526A (en) 1991-09-23 1993-07-20 Florida State University Metal alkoxides
US5284864A (en) 1991-09-23 1994-02-08 Florida State University Butenyl substituted taxanes and pharmaceutical compositions containing them
US5262409A (en) 1991-10-11 1993-11-16 Fred Hutchinson Cancer Research Center Binary tumor therapy
US5294737A (en) 1992-02-27 1994-03-15 The Research Foundation State University Of New York Process for the production of chiral hydroxy-β-lactams and hydroxyamino acids derived therefrom
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
EP0982028A1 (en) * 1998-08-20 2000-03-01 Aventis Pharma S.A. New use of taxoid derivatives

Similar Documents

Publication Publication Date Title
JP2004536790A5 (ja)
KR100334051B1 (ko) 탁산유도체를함유하는항종양조성물
ES2282400T3 (es) Composiciones antitumorales que contienen derivados de taxano.
JP5579715B2 (ja) cdk阻害剤および抗悪性腫瘍剤を含む治療用組合せ
EP1827437B1 (en) Combinations of therapeutic agents for treating cancer
AU758191B2 (en) Antitumor composition containing a synergistic combination of an anthracycline derivative with a camptothecin derivate
JP5235304B2 (ja) 抗癌療法
Kudelka et al. An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix
EP1261374A2 (en) Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
Sternberg Satraplatin in the treatment of hormone-refractory prostate cancer.
JP2007511509A (ja) Et−743およびパクリタキセルの使用を含むガンの併用療法
US20100240595A1 (en) Improved Antitumoral Treatments
RU2005132175A (ru) Комбинированное лечение опухолей, включающее неморубицин и лучевую терапию
AU774393B2 (en) Anti-tumor synergetic composition
EP2344156A1 (en) Therapeutic combination comprising an aurora kinase inhibitor and an antineoplastic agent
Hanauske Recent advances in anticancer drug development